This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
3 Medical Stocks to Consider as Markets Take a Breather
by Shaun Pruitt
These top medical stocks may be able to provide defensive safety after President Trump's tariff hikes and July's unfavorable jobs report led to a market selloff.
JNJPositive Net Change THCNegative Net Change CVSPositive Net Change
dividend-investing dividends earnings hospitals immuno-therapy investing large-cap medical oncology-screening pharmaceuticals
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
by Zacks Equity Research
MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.
PFEPositive Net Change MRKPositive Net Change MRNANegative Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
by Zacks Equity Research
Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.
REGNPositive Net Change ALNYPositive Net Change NVSPositive Net Change RHHBYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
ZTSPositive Net Change EXASPositive Net Change BNTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
by Zacks Equity Research
REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.
REGNPositive Net Change SNYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Jobs Shrink in the Summer of '25, Pre-Markets Lower
by Mark Vickery
+73K new jobs were filled last month, lower than the +100K expected. The Unemployment Rate ticked up 10 bps.
REGNPositive Net Change CVXNegative Net Change XOMNegative Net Change CLNegative Net Change
earnings interest-rate oil-energy pharmaceuticals staffing
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
by Kinjel Shah
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
AZNPositive Net Change JNJPositive Net Change
pharmaceuticals
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
by Kinjel Shah
PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change BNTXNegative Net Change
pharmaceuticals
Stock Market News for Aug 1, 2025
by Zacks Equity Research
Wall Street closed lower on Thursday, pulled down by health care and real estate stocks.
MRKPositive Net Change LLYPositive Net Change
pharmaceuticals
Buy 5 Wide Moat Stocks to Enhance Your Portfolio Returns
by Nalak Das
Boost your portfolio with ADBE, DIS, INTU, ROL and JNJ as these five wide moat stocks poised for growth and strong returns.
JNJPositive Net Change DISNegative Net Change ADBENegative Net Change INTUNegative Net Change ROLPositive Net Change
business-services computers consumer-discretionary pharmaceuticals
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
by Ahan Chakraborty
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
BCRXNegative Net Change IONSPositive Net Change NTLANegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
by Zacks Equity Research
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.
JNJPositive Net Change TEVANegative Net Change ABBVPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
by Zacks Equity Research
ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.
RHHBYNegative Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
by Zacks Equity Research
BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.
BMYPositive Net Change PFEPositive Net Change EXELPositive Net Change BNTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat
by Zacks Equity Research
BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.
DRRXNegative Net Change CRMDNegative Net Change BHCNegative Net Change ARVNNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
by Zacks Equity Research
SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.
REGNPositive Net Change SNYPositive Net Change AZNPositive Net Change VIGLNo Net Change
pharmaceuticals
Company News for Jul 31, 2025
by Zacks Equity Research
Companies in The News Are: MO, AEP, GSK, EA
GSKPositive Net Change AEPPositive Net Change MONegative Net Change EAPositive Net Change
pharmaceuticals utilities
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
by Zacks Equity Research
Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.
AZNPositive Net Change NVSPositive Net Change BIIBPositive Net Change IONSPositive Net Change
biotechs earnings medical pharmaceuticals
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
by Zacks Equity Research
GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.
GSKPositive Net Change JNJPositive Net Change VIRNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.
RDYNegative Net Change AMGNPositive Net Change TEVANegative Net Change ALVONegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
by Ahan Chakraborty
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
by Ekta Bagri
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech
ILMNNegative Net Change BEAMNegative Net Change EDITNegative Net Change NTLANegative Net Change PRMEPositive Net Change CRSPNegative Net Change
biotechnology biotechs gene-editing gene-therapy genetics genomics medical pharmaceuticals
Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?
by Kanishka Das
MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change VRNAPositive Net Change
pharmaceuticals
Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?
by Ekta Bagri
Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets.
BMYPositive Net Change MRKPositive Net Change AMGNPositive Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Broadcom, Berkshire Hathaway, Johnson & Johnson, Oil-Dri Corp. of America and Park Aerospace
by Zacks Equity Research
Broadcom, Berkshire Hathaway, and J&J headline a strong slate of stocks, with rising momentum in AI, insurance, and pharma growth drivers.
JNJPositive Net Change BRK.BPositive Net Change AVGONegative Net Change PKENegative Net Change ODCNegative Net Change
aerospace industrial-products insurance pharmaceuticals semiconductor